Curasight
10.40 DKK
-6.31 %
Less than 1K followers
CURAS
Spotlight Stock Market
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-6.31 %
-6.31 %
+62.50 %
+91.18 %
+350.22 %
+111.58 %
+77.91 %
-32.80 %
-25.47 %
Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.
Read moreMarket cap
498.4M DKK
Turnover
1.19M DKK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Latest research
Latest analysis report
Released: 22.12.2025
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
26.2
2026
Annual report '25
23.4
2026
Interim report Q1'26
27.8
2026
Interim report Q2'26
All
Research
Webcasts
Press releases
ShowingAll content types
Curasight: Resolutions of the Extraordinary General Meeting December 2025
Curasight (One-pager): Entering Clinical Validation of a uPAR Theranostic Platform
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
